CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
52.06
+1.07 (2.10%)
At close: Apr 28, 2026, 4:00 PM EDT
51.97
-0.09 (-0.17%)
After-hours: Apr 28, 2026, 7:52 PM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 70.29, with a low estimate of 44 and a high estimate of 110. The average target predicts an increase of 35.02% from the current stock price of 52.06.
Analyst Consensus: Buy
* Price targets were last updated on Mar 17, 2026.
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 7 | 7 | 7 | 7 | 6 | 6 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 20 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $105 → $110 | Buy | Reiterates | $105 → $110 | +111.29% | Mar 17, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $74 → $76 | Strong Buy | Maintains | $74 → $76 | +45.99% | Feb 17, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $40 → $45 | Hold | Maintains | $40 → $45 | -13.56% | Feb 13, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $62 → $74 | Buy | Maintains | $62 → $74 | +42.14% | Feb 13, 2026 |
| Needham | Needham | Strong Buy Maintains $80 → $82 | Strong Buy | Maintains | $80 → $82 | +57.51% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
31.86M
from 3.51M
Increased by 807.72%
Revenue Next Year
86.83M
from 31.86M
Increased by 172.52%
EPS This Year
-5.02
from -6.47
EPS Next Year
-4.15
from -5.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 106.1M | 264.1M | ||||||
| Avg | 31.9M | 86.8M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2,921.4% | 728.9% | ||||||
| Avg | 807.7% | 172.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.42 | -0.65 | ||||||
| Avg | -5.02 | -4.15 | ||||||
| Low | -6.70 | -6.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.